Skip to main content
Download PDF

Sexually dimorphic roles for the type 2 diabetes-associated C2cd4b gene in murine glucose homeostasis

Diabetologia volume 64, pages 850–864 (2021)Cite this article

Abstract

Aims/hypothesis

Variants close to the VPS13C/C2CD4A/C2CD4B locus are associated with altered risk of type 2 diabetes in genome-wide association studies. While previous functional work has suggested roles for VPS13C and C2CD4A in disease development, none has explored the role of C2CD4B.

Methods

CRISPR/Cas9-induced global C2cd4b-knockout mice and zebrafish larvae with c2cd4a deletion were used to study the role of this gene in glucose homeostasis. C2 calcium dependent domain containing protein (C2CD)4A and C2CD4B constructs tagged with FLAG or green fluorescent protein were generated to investigate subcellular dynamics using confocal or near-field microscopy and to identify interacting partners by mass spectrometry.

Results

Systemic inactivation of C2cd4b in mice led to marked, but highly sexually dimorphic changes in body weight and glucose homeostasis. Female C2cd4b mice displayed unchanged body weight compared with control littermates, but abnormal glucose tolerance (AUC, p = 0.01) and defective in vivo, but not in vitro, insulin secretion (p = 0.02). This was associated with a marked decrease in follicle-stimulating hormone levels as compared with wild-type (WT) littermates (p = 0.003). In sharp contrast, male C2cd4b null mice displayed essentially normal glucose tolerance but an increase in body weight (p < 0.001) and fasting blood glucose (p = 0.003) after maintenance on a high-fat and -sucrose diet vs WT littermates. No metabolic disturbances were observed after global inactivation of C2cd4a in mice, or in pancreatic beta cell function at larval stages in C2cd4a null zebrafish. Fasting blood glucose levels were also unaltered in adult C2cd4a-null fish. C2CD4B and C2CD4A were partially localised to the plasma membrane, with the latter under the control of intracellular Ca2+. Binding partners for both included secretory-granule-localised PTPRN2/phogrin.

Conclusions/interpretation

Our studies suggest that C2cd4b may act centrally in the pituitary to influence sex-dependent circuits that control pancreatic beta cell function and glucose tolerance in rodents. However, the absence of sexual dimorphism in the impact of diabetes risk variants argues for additional roles for C2CD4A or VPS13C in the control of glucose homeostasis in humans.

Data availability

The datasets generated and/or analysed during the current study are available in the Biorxiv repository (www.biorxiv.org/content/10.1101/2020.05.18.099200v1). RNA-Seq (GSE152576) and proteomics (PXD021597) data have been deposited to GEO (www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE152576) and ProteomeXchange (www.ebi.ac.uk/pride/archive/projects/PXD021597) repositories, respectively.

Graphical abstract

figure b

Introduction

Type 2 diabetes risk is the product of both environmental and genetic factors. More than 200 loci have now been described as affecting the diabetes risk score [1]. While most of these impact insulin secretion [2], the identified variants usually lie within or between neighbouring genes and in only a few cases have the causal gene(s) been firmly established [3, 4].

Chromosome 15q hosts a risk locus close to the VPS13C, C2CD4A and C2CD4B genes [5], which is associated with impaired proinsulin processing. Deletion of Vps13c (which encodes a lipid transporter [6]) selectively from the pancreatic beta cell [7] has little effect on glucose homeostasis in the mouse. This finding argues that the other genes at this locus contribute towards the effect(s) of risk variants in humans.

Previous expression quantitative trait locus (eQTL) studies have demonstrated altered expression of VPS13C and C2CD4A [7], as well as C2CD4B [8], in islets from individuals carrying risk alleles. Recently, Kycia et al [9] reported that expression of C2CD4B, but not C2CD4A or VPS13C, was affected by risk alleles. However, the direction of effects of risk alleles differed between the reports, with expression lowered uniquely in females in the study of Mehta et al [7] but increased in the study by Kycia et al [9]. However, both of these studies involved relatively small sample numbers. These limitations emphasise the need for interventional studies involving gene inactivation in tractable model systems, such as rodents or fish, as an alternative means of understanding the roles of these genes in metabolic homeostasis.

C2CD4A and C2CD4B (also called NLF1 and NLF2) [10] encode low molecular mass (39 kDa) proteins of presently unknown function. Unlike the homologous C2CD4C gene (expressed from a distinct locus on chromosome 19 in Homo sapiens), neither C2 calcium dependent domain containing protein (C2CD)4A nor C2CD4B possess a canonical Ca2+/phospholipid-binding C2-domain [11]. A partly functional Ca2+-binding domain may be present in C2CD4B (see electronic supplementary material [ESM] Fig.1). Given the essential role for Ca2+ in the control of insulin and other hormone secretion [12], an interaction with Ca2+ might provide a means through which C2CD4A or C2CD4B influence these processes.

Originally described in endothelial cells as having a largely nuclear distribution, and inducible by cytokines [10], the role of C2CD4B has not been explored previously in beta cells or other metabolically relevant cell types. Nonetheless, silencing of the single homologous C2cd4a/b gene in the zebrafish (Danio rerio) led to a decrease in beta cell mass [13]. In contrast, silencing of the Drosophila melanogaster C2CD4A homologue, spenito (also known as nito), increased circulating levels of the insulin-like molecule IIp2HF [14]. Inactivation of C2cd4c has no detectable effect on pancreatic development in mice [11].

A recent study [15] has indicated that regulation of C2cd4a expression in islets by forkhead box O1 (FOXO1) may be important for the control of insulin secretion. Thus, animals inactivated selectively in the beta cell for C2cd4a displayed abnormal insulin secretion in response to exposure to glucose plus arginine (the effects on secretion stimulated by glucose alone were not reported), as well as glucose intolerance in vivo and abnormal expression of beta cell signature and ‘disallowed’ genes [16]. However, these studies used the Ins2-dependent rat insulin promoter (RIP) to drive Cre expression, a strategy complicated by off-target recombination and ectopic expression of human growth hormone [17].

Here, we use the more direct approach of inactivating C2cd4b and C2cd4a globally in the mouse, and of deleting their homologue, C2cd4a, in the developing zebrafish (D. rerio), to explore the role of these genes in glucose homeostasis.

Methods

For detailed Methods and the reagents list, please refer to the ESM Methods.

Mouse generation

C2cd4a (C2cd4a-Del1724-EM1-B6N) and C2cd4b (C2cd4bem2Wtsi) mouse strains were generated at the International Mouse Phenotyping Consortium (IMPC; www.mousephenotype.org/data/genes/MGI:3645763 and www.mousephenotype.org/data/genes/MGI:1922947, respectively; accessed November 2020), using CRISPR/Cas9. In vitro fertilisation was performed into super-ovulated C57BL/6 females, producing mixed B6N/B6J offspring, which were subsequently inter-crossed. Lean and fat mass were measured using an EchoMRI Quantitative Whole Body Composition analyser (Zinsser Analytic, USA) on unanaesthetised animals. The high-fat and -sucrose diet (HFD) contained 58% fat and 25% carbohydrate (catalogue no. D12331; Research Diets, New Brunswick, NJ, USA), given from 6 weeks of age.

Glucose homeostasis

Animals were fasted overnight prior to experiments. For IPGTTs, glucose (1 g/kg body weight) was injected into the abdomen. In OGTTs, glucose (2 g/kg body weight) was administered directly into the gut via oral gavage. Blood glucose levels were recorded using an automatic glucometer (Accucheck; Roche Diagnostics, Burgess Hill, UK). For insulin tolerance tests, animals were fasted for 5 h prior to experiments. Insulin was injected into the abdomen: Male and female mice (both C2cd4b-null and WT) on the regular chow (RC) diet were injected with a 1 or 0.75 U/kg body weight of insulin, respectively. HFD-fed male and female mice were injected with 1.5 or 0.75 U/kg body weight of insulin, respectively. Blood glucose levels were measured post injection at the time points indicated. To measure insulin secretion in vivo, animals were fasted overnight and glucose (3 g/kg body weight) was injected into the abdomen. Blood insulin levels were measured using an Ultra-Sensitive Mouse Insulin ELISA Kit (90,080; Crystal Chem, Zaandam, the Netherlands).

Measurement of circulating hormone levels

For assessment of follicle-stimulating hormone (FSH) and luteinising hormone (LH), gonadectomy was conducted under isoflurane anaesthesia [18]. Plasma levels of testosterone and oestradiol (E2) were determined by ELISA (Enzo Life Sciences, Exeter, UK, and BioVision, Cambridge BioScience, Cambridge, UK, respectively) 2 weeks later [18].

Insulin secretion from isolated islets

Islet isolation [19] and measurements of insulin secretion [20] were measured as described previously, using ten size-matched islets incubated in triplicate in HEPES-buffered Krebs-Ringer medium (KREBH) and either 3 mmol/l glucose, 17 mmol/l glucose or 20 mmol/l KCl at 37°C. Insulin was measured using an Insulin Ultra-Sensitive Kit (Mercodia, Uppsala, Sweden).

Generation of C2CD4A and C2CD4B FLAG- and -green fluorescent protein-tagged constructs

Human C2CD4A and C2CD4B cDNA sequences were cloned in-frame into plasmid P3XFLAG-CMV-14 (Addgene, www.addgene.org) to provide a C-terminal 3×FLAG epitope tag. Green fluorescent protein (GFP)-tagged proteins were generated by inserting the human C2CD4A and C2CD4B cDNA sequences into the C-terminus of GFP using plasmid pEGFP-C1 (Addgene).

C2CD4A/B intracellular translocation

INS1(832/13) cells [21] were grown on coverslips and transfected with either GFP-tagged C2CD4A, C2CD4B or synaptotagmin-1 (Syt1)-containing constructs. At 24 h post transfection, cells were incubated for 1 h at 37°C with aerated KREBH solution. Cells were confirmed to be mycoplasma free prior to experiments.

Study approval

All mouse in vivo procedures were conducted in accordance with the UK Home Office Animal (Scientific Procedures) Act of 1986 (Project licence PA03F7F0F to IL) and approved by the Imperial College Animal Welfare and Ethical Review Body. All zebrafish work was approved by the ethical committee of the University of Liège (protocol no. 13-1557) or under European Union and German laws (Tierschutzgesetz), and with the approval of the TU Dresden and the Landesdirektion Sachsen (approval licence number: TVV 45/2018).

Zebrafish maintenance and generation of transgenic lines

Zebrafish (D. rerio) were obtained from the Zebrafish International Resource Center (Zfin, Eugene, OR, USA) or from the European Zebrafish Resource Center at Karlsruhe Institute of Technology (www.ezrc.kit.edu/), and then bred at the host laboratory (University of Liège [ULg], Liège, Belgium, or Universität Dresden, Dresden, Germany, respectively). Genetically modified zebrafish were developed at the host laboratories. Zebrafish were raised and cared for according to standard protocols [22]. The transgene rs7163757C-cfos:eGFP was constructed by introducing a 1303 bp region carrying the genome-wide association study (GWAS)-identified gene variant rs7163757-C upstream of a c-fos minimal promoter driving enhanced GFP (EGFP) expression (pGW_cfos-EGFP) [23, 24] via Gateway LR recombination (Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA). The transgene was injected into zebrafish embryos and GFP expression patterns were analysed during development, in adulthood and in offspring, using a confocal microscope.

Whole-mount in situ hybridisation and immunohistochemistry on zebrafish embryos

Double fluorescent whole-mount in situ hybridisations were performed as previously described [25] with the antisense RNA probe for the different genes prepared as described [26]. Immunohistochemistry on whole-mount embryos was performed as previously described [27]. The proteins analysed were GFP, insulin, glucagon and somatostatin. Images were acquired with a confocal microscope and processed with ImageJ (https://imagej.nih.gov/ij/; accessed December 2019) and figureJ (https://imagej.net/FigureJ).

Pericardial glucose injection and live imaging in zebrafish larvae

Glucose injection and live imaging of zebrafish primary islets were performed as described previously [28].

Blood glucose measurements in adult zebrafish

Adult zebrafish were fasted for 24 h before glucose measurements. For post-prandial measurements, fasted fish were fed with live brine shrimp. Blood was collected from euthanised fish with a microcapillary needle and glucose levels were measured using a glucometer.

Immunofluorescence analysis of pancreatic slices

Mouse pancreases were dissected at 24 or 25 weeks of age. Pancreases were fixed in 4% (wt/vol.) paraformaldehyde and embedded in paraffin for the measurement of insulin and glucagon via immunofluorescence.

Homogeneous time-resolved fluorescence (HTRF) assay

The Insulin Ultra-Sensitive Kit (ref. 62IN2PEH; Cisbio, Codolet, France) was used according to the manufacturer’s instructions to measure released or total insulin levels in mouse samples. Each sample was measured in duplicate and incubated with europium cryptate and XL665 antibodies overnight before measuring the Fӧrster resonance energy transfer (FRET) efficiency.

Intracellular free [Ca2+] measurements

Mouse islets were isolated and incubated with fluo2-AM (10 μmol/l; Teflabs, Austin, TX, USA) diluted in a KREBH buffer containing 3 mmol/l glucose. Imaging was performed essentially as described previously [29].

Whole-cell voltage-clamp electrophysiology

Measurements were performed on single beta cells isolated from wild-type (WT) and C2cd4b-knockout mice. Starting from a holding potential of −80 mV, and voltage-dependent Ca2+ currents (VDCC) currents were generated through application of sequential 10 mV depolarising steps ranging from −70 mV to 70 mV (500 ms).

Sample preparation for RNA sequencing

Islets from five male mice/genotype at 22 weeks of age on regular chow diet were used for RNA purification. Generation of double-stranded cDNA and library construction were performed using NEBNext Ultra II Directional RNA Library Prep Kit for Illumina (NEB, Hitchin, UK). Sequencing was performed by the Imperial BRC Genomics Facility (Imperial College London, UK) as 75 bp paired end reads on a HiSeq4000 according to Illumina specifications. Data are archived in the GEO repository (www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE152576).

Quantitative reverse transcription PCR

Quantitative reverse transcription PCR (RT-qPCR) was performed in triplicate using SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA, USA) and primers for mouse C2cd4a and β-actin genes.

Immunofluorescence and imaging for subcellular localisations

Rodent (MIN6 [15], INS1[832/13] [21]) or human (EndoCβH1 [30]) beta cell lines (previously confirmed as being mycoplasma free) were cultured for 12 h or 24 h post transfection (with C2CD4A- or C2CD4B-FLAG tagged constructs) and fixed in 4% (wt/vol.) paraformaldehyde (Sigma-Aldrich, Gillingham, Dorset, UK) before being incubated with anti-FLAG antibodies. Images were collected by a spinning disk microscope and a confocal inverted microscope.

Immunoprecipitation and mass spectrometry

Mycoplasma-free MIN6 cells grown in standard culture conditions [31] were transfected in duplicate with FLAG-tagged-C2CD4A or -C2CD4B expressing plasmids or with a FLAG tag-only expressing plasmid using Lipofectamine 2000 (Thermo Fisher Scientific). Immunoprecipitation and affinity purification-MS (AP-MS) analysis were performed, as previously described [32], with minor modifications. The mass spectrometry proteomics data have been deposited to the ProteomeXchange repository (www.ebi.ac.uk/pride/archive/projects/PXD021597).

Statistical analysis

Blinding was carried out for all mouse in vivo experiments. Data were analysed using GraphPad Prism 8.0 (San Diego, CA, USA; www.graphpad.com/scientific-software/prism/, accessed 1 December 2019). A p-value <0.05 was considered significant.

Results

C2CD4A and C2CD4B expression in mouse and human islets

Human C2CD4A and C2CD4B are 83% homologous. Like their murine homologues, the two human genes are predicted to have evolved from a common ancestor (see phylogenetic tree, ESM Fig. 2a). Conservation of genomic architecture (synteny) at this locus argues for direct homology between the human and murine forms of each gene. The zebrafish (D. rerio) possesses two C2cd4-like genes homologous to H. sapiens and Mus musculus: C2cd4a and C2cd4c (ESM Fig. 2a). Scrutiny of gene expression databases (http://Biogps.org, accessed March 2020), and previous publications [33, 34], reveals approximately tenfold higher levels of C2cd4b than C2cd4a mRNA in mouse islets and purified mouse beta cells (ESM Table 1). In contrast, roughly equal levels of C2CD4A and C2CD4B mRNA are present in human islets [35] and purified beta cells [36]. Expression of both genes was detected in the pituitary in both human and mice (data source: GTEx data, analysed in The Human Protein Atlas; www.proteinatlas.org/ENSG00000198535-C2CD4A/tissue and www.proteinatlas.org/ENSG00000205502-C2CD4B/tissue; accessed November 2020). C2cd4a and C2cd4b were both upregulated in pancreatic islets of high-fat-diet--fed DBA2J mouse model of diabetes following 30 and 90 days of the diet vs RC-fed mice (ESM Fig. 3a,b) [37]. No evidence of C2CD4A or C2CD4B upregulation was observed in the islets of individuals with type 2 diabetes vs normoglycaemic control participants [38].

Examination of the human VPS13C/C2CD4A/C2CD4B locus revealed multiple regulatory elements (Fig. 1), consistent with recent findings [9]. A SNP, rs7163757, has recently been shown by fine mapping as the likely causal variant for type 2 diabetes risk at this locus [9]. Correspondingly, CRISPR activation (CRISPRa) or CRISPR interference (CRISPRi) at the rs7163757 site has the most marked effects on neighbouring genes [39], consistent with this being the effector variant (SNP). To explore in more detail the potential role of the enhancer around the diabetes risk variant rs7163757 [9] and whether it may play a role in gene expression in disease-relevant tissues (notably the islet and brain/pituitary), we introduced a reporter bearing 1303 bp nucleotides of the human sequence into the zebrafish genome, controlling the production of GFP from a minimal cFos promoter (ESM Fig. 2b). Expression was restricted to the endocrine pancreas and brain at all stages (ESM Fig. 2c,e), and was detected in all islet cell types, most strongly in delta cells (ESM Fig. 2d). No significant differences were seen in the pattern of expression in embryos expressing either the C- or the T variants, with 10% (8/80 or 10/100, respectively) of embryos showing fluorescence in the pancreas.

Fig. 1
figure 1

Genomic context of type 2 diabetes variants in the VPS13C/C2CD4A/C2CD4B locus. SNP at rs7163757 is located in an open chromatin region between C2CD4A and C2CD4B, as assessed by Assay for Transposase-Accessible Chromatin sequencing (ATAC-seq) data. Chromatin immunoprecipitation and next generation sequencing (ChIP-seq) data reveals binding sites for transcription factors involved in the development and function of beta cells, including forkhead box protein A2 (FOXA2), NK2 homeobox 2 (NKX2.2), NK6 homeobox 1 (NKX6.1) and pancreatic and duodenal homeobox 1 (PDX1). MED1, mediator complex subunit 1. Functional PP, functional posterior probability. Data from [39]

Full size image

Whole-mount fluorescent in situ hybridisation of 30 h-post-fertilisation (hpf) embryos revealed that endogenous c2cd4a is expressed in the forebrain (ESM Fig. 2f), ventral spinal cord (ESM Fig. 2g) and pancreas (ESM Fig. 2c,h). Double fluorescent in situ hybridisation revealed presence of the c2cd4a transcript in sst2+, ins+ and gcgb+ cells (ESM Fig. 2d,i–k).

Role of c2cd4a in the zebrafish larvae

Zebrafish possess a single gene, C2cd4a (formerly c2cd4ab), that is homologous to the two mammalian counterparts (ESM Fig. 2a). As a convenient proxy for insulin secretion in the larvae of fish inactivated for c2cd4a or in WT controls (ESM Fig.4 a,b), glucose-stimulated Ca2+ dynamics were monitored in vivo by imaging the fluorescence of a gCaMP6 transgene. Fasting and postprandial blood glucose levels were comparable between WT and c2cd4a mutant animals (ESM Fig. 4c) and glucose-induced Ca2+ changes did not differ between genotypes (ESM Fig. 4d–h). These findings argue against a role for c2cd4a in beta cell function during zebrafish development.

Effects of C2cd4b deletion on glucose homeostasis are more marked in female than male mice

Given the substantially higher expression of C2cd4b than C2cd4a in mouse islets (ESM Table 1), we studied mice in which the former gene was deleted (Fig. 2a). Inter-crossing of heterozygous animals produced pups at the expected Mendelian ratio (Fig. 2b) and resulted in complete elimination of C2cd4b mRNA from isolated islets of C2cd4b−/− mice (Fig. 2c). Female C2cd4b-null mice gained weight at the same rate as control littermates whether maintained on RC or a HFD (Fig. 2d) and no differences were apparent in fed or fasting blood glucose levels either on an RC diet (ESM Fig. 5a,c) or an HFD (Fig. 2f and ESM Fig. 5e).

Fig. 2
figure 2

Characterisation of C2cd4b-null mice. (a) C2cd4b global null mice (C2cd4bem2Wtsi) were generated by the IMPC. Using CRISPR/Cas9, the encoding exon from murine C2cd4b (exon 2) was deleted. (b) C2cd4b+/− (heterozygous) animals were setup as breeding pairs and the WT (C2cd4b+/+) and homozygous (C2cd4b−/−) littermates were studied. (c) RT-qPCR was performed on RNA from isolated islets and showed a significant decrease in C2cd4b mRNA levels in homozygous animals (p=0.0092). C2cd4b+/+ n=4, C2cd4b+/− n=3, C2cd4b−/− n=7. **p<0.01, unpaired Student’s t test. (d, e) Changes in weight of C2cd4b+/+ and C2cd4b−/− female (d) and male (e) mice over time on an RC diet or HFD. RC: female (F)+/+ n=3–6; F−/− n=4–13; male (M)+/+ n=8–12; M−/− n=10–12. HFD: F+/+ n=9–12, F−/− n=5–10–12; M+/+ n=6–12, M−/− n=7–12. (f, g) Fasting blood glucose level in female (f) and male (g) mice on an HFD were measured at 23 weeks of age. F+/+ n=9; F−/− n=5; M+/+ n=5; M−/− n=7. (h, i) Percentage of body fat (h) and lean mass (i) in males maintained on an HFD at 20 weeks of age. *p<0.05, **p<0.01, ***p<0.001, mixed-effect analysis, RC-fed WT vs RC-fed mutant mice or HFD-fed WT vs HFD-fed mutant mice at each time point (d, e), or Student’s t test (c, f–i). Data were assessed for significance using an unpaired Student’s t test or two-way ANOVA where two genotypes were compared. Values represent means ± SEM

Full size image

Beta cell mass, as assessed by histochemical analysis of pancreatic slices, was unaffected by deletion of C2cd4b in both females (ESM Fig. 6a–d) and males (ESM Fig. 6e–h).

Intraperitoneal glucose tolerance was examined for animals maintained on an RC diet or HFD from 8 to 22 weeks of age. Females displayed abnormalities at 12, 20 and 22 weeks of age when fed an RC diet (ESM Fig. 7a,c,e,g), and at 8 and 23 weeks on an HFD (ESM Fig. 8a,c,e and Fig. 3a; p < 0.001 at 22 weeks on an HFD) vs control littermates. While oral glucose tolerance was normal on in RC-fed female mice vs controls (Fig. 3c), defects were observed in HFD-fed mice (Fig. 3g). For female mice on the RC diet, these changes were associated with defective insulin secretion in vivo (Fig. 4a; p = 0.02), as also indicated by unchanged insulin levels after glucose injection despite elevated plasma glucose levels in female knockout mice maintained on an HFD (Fig. 4c). Furthermore, insulin sensitivity was not different between C2cd4b null and WT female mice (ESM Fig. 9a,c).

Fig. 3
figure 3

C2cd4b-null mice display glucose intolerance in glucose tolerance tests (IPGTTs/OGTTs). (a, b) IPGTTs were performed on female (a) and male (b) mice maintained on an RC diet, at 22 weeks of age. (c, d) OGTTs were performed on C2cd4b-null and WT female (c) and male (d) mice on an RC, at 20 weeks of age. (e, f) IPGTTs were performed on C2cd4b-null and WT female (e) and male (f) mice maintained on an HFD, at 23 weeks of age. (g, h) OGTTs were performed on C2cd4b female (g) and male (h) mice on an HFD, at 20 weeks of age. AUC analyses are also shown. The n values under bar graphs represent the number of animals used (the same number of samples were used for blood glucose and AUC graphs). *p<0.05, **p<0.01, ***p<0.001 vs mutant animal at same time point or as indicated. Blood glucose curves assessed by two-way ANOVA with Bonferroni’s multiple comparison test; AUC analyses assessed using an unpaired Student’s t test. Values represent means ± SEM

Full size image
Fig. 4
figure 4

Effect of C2cd4b deletion on in vivo glucose-stimulated insulin secretion. (a–d) In vivo insulin levels during IPGTT in C2cd4b-null and WT females (a, c) and males (b, d) on an RC diet, at 23 weeks of age (a, b) or an HFD at 19 weeks of age (c, d). RC: female (F)+/+ n=9; F−/− n=6; male (M)+/+ n=6; M−/− n=7. HFD: F+/+ n=5; F−/− n=7; M+/+ n= 7; M−/− n=7. *p<0.05, ***p<0.001, WT vs mutant animal at same time point, two-way ANOVA with Bonferroni’s multiple comparison test. Values represent mean ± SEM

Full size image

When maintained on an RC diet, male C2cd4b null mice gained weight at the same rate as WT littermates. When maintained on an HFD, in contrast to females, male mutant mice gained substantially more weight from 14 weeks of age vs WT littermates (Fig. 2d,e; p < 0.001 betwee18 and 21 weeks of age), and had raised fasting blood glucose levels (Fig. 2g; p = 0.03). However, significant differences in body fat and lean mass were not apparent (Fig. 2h,i) vs WT mice. Intraperitoneal glucose tolerance was normal in males maintained on an RC diet at most ages examined, with genotype-dependent differences only at 16 weeks (ESM Fig. 7b,d,f,h and Fig. 3b). Although unaltered in younger male mice after maintenance on an HFD (ESM Fig. 8b,d,f), glucose tolerance was impaired at 23 weeks of age by C2cd4b deletion (Fig. 3f,h) as compared with controls.

As observed in females, insulin sensitivity (ESM Fig. 9b,d) was unaltered in male C2cd4b-null mice vs littermate controls.

Effects of C2cd4b deletion on beta cell function in vitro

Glucose-stimulated insulin secretion was not different between islets from WT or C2cd4b-null female mice maintained on an RC diet (ESM Fig. 10a) but was slightly elevated in those from female null mice maintained on an HFD (ESM Fig. 10c). Likewise, in the isolated islets from female C2cd4b-null mice, we observed no alterations in glucose or KCl-stimulated stimulated Ca2+ dynamics (ESM Fig. 11a,b) or in beta cell–beta cell coupling (ESM Fig. 11c–f). Correspondingly, no changes in voltage-activated Ca2+ currents were apparent in patch-clamp recordings (ESM Fig. 12a–c).

In line with the above findings, massive parallel sequencing (RNA-Seq) of islets from C2cd4b−null or control animals confirmed the lowering of C2cd4b expression in islets of null mice vs WT mice, and revealed a significant (~75%) increase in C2cd4a expression (ESM Table 2), though this was not confirmed by independent qRT-PCR analysis (data not shown). However, no other mRNAs were significantly affected by C2cd4b deletion (ESM Table 2).

Glucose or KCl-stimulated insulin secretion from isolated islets were also unaltered in male C2cd4b-null mice vs littermate controls (ESM Fig. 10 b,d).

Effects of C2cd4b deletion on pituitary function

Given the absence of clear defects in insulin secretion in isolated C2cd4b-null islets, and the expression of both C2cd4a and C2cd4b in the pituitary (data source: GTEx data, analysed in The Human Protein Atlas; www.proteinatlas.org/ENSG00000198535-C2CD4A/tissue and www.proteinatlas.org/ENSG00000205502-C2CD4B/tissue; Fig. 5a), we next assessed whether deletion of this gene might affect the production of sex hormones and, thus, provoke gender-specific differences in glucose homeostasis. E2 and testosterone levels were unaltered in both male and female C2cd4b-null mice maintained on an RC diet or HFD vs WT animals (Fig. 5b,c). In order to remove the negative feedback loop through which hormones secreted from the gonads repress FSH and LH release from the pituitary gland, animals between 12 and 15 weeks of age were gonadectomised prior to these experiments. Compared with WT littermates, female C2cd4b-null mice displayed ~50% lower circulating FSH levels, with no difference in LH levels (Fig. 5d,f; p = 0.003). No differences in LH or FSH levels were apparent between WT and C2cd4b-null male mice (Fig. 5e,g).

Fig. 5
figure 5

Effect of deletion of C2cd4b on sex hormones and hormone release from the pituitary gland. (a) RT-qPCR on samples from the pituitary glands shows basal level of mRNA expression of C2cd4b in animals deleted for this gene compared with WT mice. (b, c) Measurement of E2 and testosterone levels upon deletion of C2cd4b in female and male mice maintained on either an RC diet or an HFD. (d, e) Circulating LH levels in C2cd4b-null and WT female (d) and male (e) mice after injections with saline (154 mmol/l NaCl; vehicle), E2 or testosterone (animals were maintained on an RC diet). (f, g) Circulating FSH levels in C2cd4b-null and WT female (f) and male (g) mice after injections with saline (vehicle), E2 or testosterone (animals were maintained on an RC diet). Female (F)+/+ n=6, F−/− n=5; male (M)+/+ n=4; M−/− n=5. **p<0.01, ***p<0.001, unpaired Student’s t test. Values represent mean ± SEM

Full size image

C2cd4a-null mice display no metabolic abnormalities

To determine whether C2cd4a inactivation might also have an impact on glucose homeostasis, we next examined metabolic phenotypes in male and female C2cd4a-null mice (ESM Fig. 13a–c). In contrast to their C2cd4b-null counterparts, C2cd4a-null mice displayed no evident metabolic abnormalities up to 22 weeks of age, with neither weight gain, glucose homeostasis nor insulin secretion differing between WT and null mice for either sex (ESM Fig. 13d–i). Likewise, as measured in vitro, glucose and KCl (depolarisation)-stimulated insulin secretion were unaltered in islets isolated from male C2cd4a-null mice (ESM Fig. 13j).

C2CD4A but not C2CD4B C2 domains support Ca2+-dependent intracellular translocation

We next sought to explore the mechanism(s) through which C2CD4B or C2CD4A may influence beta cell (and, potentially, pituitary gonadotroph) function. Both proteins have been suggested to lack a functional C2 domain [11], consistent with a reported localisation in the nucleus in COS7 cells [10]. In contrast to earlier findings reporting nuclear subcellular localisation, when overexpressed as GFP- or FLAG- tagged chimaeras in rodent (MIN6, INS1[832/13]) or human (EndoCβH1) beta cell lines, C2CD4A and C2CD4B were found at the plasma membrane and in the cytosol and the nucleus (ESM Fig.14 and ESM Fig.15). In the majority of cells, C2CD4A and C2CD4B were primarily localised to the cytoplasm and nucleus. Co-localisation with readily identified intracellular sub-compartments, including the secretory granule (insulin), trans-Golgi network (TGN46), endosome/lysosome (LAMP1) or endoplasmic reticulum (ER; KDEL), was not apparent in the above cell lines (ESM Fig. 16; data only shown for MIN6 cells but results were consistent in all three cell lines).

The above findings suggested that the C2 domain of either protein may bind to Ca2+ and contribute to localisation at, and/or shuttling between, subcellular compartments in living cells. To test this hypothesis, we explored phospholipid-dependent recruitment of these proteins to the plasma membrane in INS1(832/13) beta cells [21] expressing either a control construct, in which Syt1 (bearing five C2 domains) was fused to GFP [40] or equivalent C2CD4A or C2CD4B constructs (N-terminal linkage). In response to an increase in intracellular free Ca2+, provoked by 50 μmol/l extracellular Ca2+ and the calcium ionophore ionomycin (50 ng/ml), Syt1–GFP translocated from intracellular (likely ER-bound) sites to the plasma membrane. This movement was readily visualised by simultaneous live-cell wide-field and total internal reflection of fluorescence (TIRF) imaging (Fig. 6a,b,d). A similar, but smaller change in the localisation of C2CD4A–GFP in response to Ca2+ was also observed. In contrast, no response was detected for C2CD4B-GFP (Fig. 6c,e–g).

Fig. 6
figure 6

Changes in C2CD4A and C2CD4B localisation in response to increased intracellular [Ca2+]. (a) Schematic showing the principle of Ca2+-dependent translocation of C2 domains to the plasma membrane. The ribbon diagram reproduced from [57] under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium. (b) Localisation of GFP-Syt1 in cells incubated in KREBH buffer with 3 mmol/l glucose, shown before and after an increase in intracellular Ca2+ levels (achieved by addition of 50 ng/ml ionomycin), obtained by simultaneous wide-field and TIRF image acquisition (positive control). (c) Localisation of GFP-tagged C2CD4A and -C2CD4B before and after addition of ionomycin, obtained by simultaneous wide-field and TIRF image acquisition. (d, f) Time courses for the translocation of the GFP-tagged proteins, Syt1 (d), C2CD4A (e) or C2CD4B (f) obtained by TIRF imaging before and after addition of ionomycin (iono). (d–f) Solid black lines represent mean; SEM shown by grey bars. (g) Assessment of fluorescence intensity change (%) reveals an increase in C2CD4A intensity at the plasma membrane after the imposed increase in intracellular Ca2+ levels, which was similar to that observed for Syt1 protein translocation, whilst C2CD4B translocation was significantly lower than Syt1. For each condition, n=3 independent experiments were performed; n=44 cells were tracked in Syt1, n=29 cells were tracked in the case of C2CD4A, and n=30 cells were tracked in the case of C2CD4B. Scale bars = 10 μm. **p<0.01, one-way ANOVA

Full size image

Identification of C2CD4A and C2CD4B binding partners by mass spectrometry

The above experiments demonstrated that C2CD4A, and possibly C2CD4B, may participate in Ca2+-dependent signal transduction. To gain further insight into possible mechanisms of action, we performed an unbiased proteomic screen using immunoprecipitation and mass spectrometry to identify potential binding partners. Normalising to the negative control, and ranking in order of protein abundance, we generated lists of possible interacting proteins for human C2CD4A, C2CD4B (ESM Tables 3,4) or both (ESM Table 5). MIN6 cells transfected with human C2CD4A or C2CD4B were used for this analysis, given the low transfection efficiency of human-derived EndoCβH1 cells. Interacting partners included proteins involved in Ca2+ binding (torsin-2A [TOR2A] and EF-hand calcium-binding domain-containing protein 5 [EFCAB5; [41] and www.genecards.org/), NF-κB signalling (sequestosome-1 [SQSTM1] and programmed cell death protein 11 [PDCD11]) and protein trafficking (proprotein convertase subtilisin/kexin type 9 [PCSK9], neural precursor cell expressed, developmentally down-regulated 4, E3 ubiquitin protein ligase [NEDD4], Ras-proximate-1 [Rap1] and GTPase-activating protein [GAP2]). Receptor-type tyrosine-protein phosphatase-like N (PTPRN; insulinoma-associated protein 2 [IA-2]) and PTPRN2; phogrin/IA-2β/islet cell antigen 512 [ICA512]) bound to both C2CD4A and C2CD4B. These protein tyrosine phosphatase-like transmembrane proteins are granule-resident and implicated in granule trafficking and exocytosis [42].

Discussion

The overall aim of this study was to examine the biological roles of C2cd4b and C2cd4a in vivo, focusing on the pancreatic beta cell and pituitary gland. These questions have been pursued using mouse and fish knockout models and relevant cell lines. In contrast to earlier findings [15], we observed that global C2cd4a deletion in the mouse exerted no effects on insulin secretion in vitro or in vivo. These findings are consistent with the considerably (tenfold) lower expression of C2cd4a than C2cd4b in mouse islets and mouse-derived beta cell lines (ESM Table 1), though we should emphasise that no attempt was made here to quantify protein (rather than mRNA) levels. The reasons for the differences between the present study and that of Kuo et al [15] with respect to C2cd4a are presently unclear.

Deletion of C2cd4b leads to weight gain in males, but defective insulin secretion in female mice

Our findings reveal a strikingly sexually dimorphic phenotype of C2cd4b-null mice, which is also strongly dependent upon diet. In contrast to females, male C2cd4b null mice displayed no evident metabolic abnormalities at most ages when maintained on an RC diet. Although mutant male mice exhibited a substantial increase in body weight on the HFD, fasting glucose and glucose tolerance were impaired only in older (>20 weeks) animals. In stark contrast, female mutant mice displayed abnormal glucose tolerance from as early as 12 weeks when fed an RC diet and 8 weeks when fed an HFD (with a tendency towards abnormal glucose tolerance [p > 0.05] being observed at 8 weeks in RC-fed mice), despite unaltered body weight. Non-significant changes in lean mass were observed in male C2cd4b-null mice on HFD, which are reminiscent of findings from the IMPC (www.mousephenotype.org/data/genes/MGI:1922947, accessed November 2020) when this line was fed an RC diet. The mechanisms underlying these changes remain unclear but are unlikely to involve elevated testosterone levels in knockout animals, since these were not observed in our study.

Although earlier human studies were not stratified by sex, we note that a statistically significant (p = 0.004) impact of the human type 2 diabetes-associated variant rs7172432 (which is in perfect linkage disequilibrium with rs7163757: R2 = 1.0) [15] at the VPS13C/C2CD4A/C2CD4B locus on waist circumference has previously been reported [43], and may be related to the alterations in body weight we observed here in male C2cd4b-knockout mice.

What factors underlie these sex-dependent differences in insulin secretion between WT and C2cd4b-null mice? Our findings suggest that beta cell-extrinsic mechanisms, possibly involving circulating factors, contribute to (and may even be the drivers of) altered insulin secretion in the living animal. Potential contributors are changes in FSH levels [44, 45] in female C2cd4b-null mice, reflecting altered expression of the gene in the pituitary. Decreased FSH production is expected, in turn, to decrease circulating oestrogen levels. We note, however, that measurements of oestrogen are complicated in fertile mice due to fluctuations in the oestrous cycle [46]. Positive actions of oestrogen on beta cell insulin content (via oestrogen receptor α) and secretion (via oestrogen receptor β) are well known [44, 47] and may thus underlie the weaker insulin secretion in C2cd4b-knockout mice. Consistent with a requirement for sexual maturity, no differences were apparent in beta cell function between genotypes in the living fish embryo (ESM Fig.4) at stages where differences in circulating sex hormones are not anticipated, and fasting blood glucose levels did not differ between WT and knockout fish at adult stages. These findings are in contrast to earlier studies in zebrafish larvae using oligonucleotide-mediated C2cd4a gene knockdown [13], which reported alterations in beta cell mass.

Such sexual dimorphism on the impact of variants at this locus, however, has not been reported in human GWAS data [48, 49]. One possible explanation is that dimorphism in mice reflects well-known differences in the response of males and females to HFD [50]. More likely, in our view, is that in rodent islets (and pituitary; see below), C2cd4b expression predominates over C2cd4a, while in humans, C2CD4A and C2CD4B expression are comparable. Consequently, in humans, changes in both C2CD4A and C2CD4B may mediate the effect of the GWAS signal for type 2 diabetes, dampening a sexually dimorphic effect of changes in C2CD4B expression.

Might altered genetic risk for type 2 diabetes in humans result from changes in C2CD4A or C2CD4B expression in the brain? Importantly, high levels of expression of C2CD4A and C2CD4B in the pituitary (GTEx data, The Human Protein Atlas; www.proteinatlas.org/ENSG00000198535-C2CD4A/tissue and www.proteinatlas.org/ENSG00000205502-C2CD4B/tissue; accessed November 2020) are consistent with this view. Correspondingly, an eQTL for C2CD4A is reported for rs7163757 in the pituitary (www.gtexportal.org/home/snp/rs7163757#sqtl-block, accessed November 2020), with a (non-significant) tendency towards decreased expression of C2CD4A and, more strongly, VPS13C in carriers of C (risk allele) vs T alleles.

Intracellular signalling by C2cd4a and C2cd4b

Our observation that neither C2CD4A nor C2CD4B are localised exclusively in the nucleus, as previously reported in COS7 cells [10], islets and MIN6 cells [15], was unexpected, but implies a more dynamic role for both C2CD4A, and possibly C2CD4B, in intracellular signalling. We note that the present study explored the subcellular distribution of the H. sapiens protein, rather than the M. musculus homologue examined previously [15], providing a potential explanation for these differences. Interestingly, predictions from the primary structure [11] indicate that neither C2CD4A nor C2CD4B (human or mouse) possesses a C2 domain with a bona fide Ca2+-binding site [51, 52]. Nevertheless, we provide a direct demonstration of Ca2+-dependent recruitment of C2CD4A to the plasma membrane (Fig. 6), whereas C2CD4B would appear to exert its function independently of Ca2+ binding.

What signalling mechanism(s) may lie downstream of C2CD4A (or C2CD4B)? The interacting protein PTPRN2 (also known as phogrin and IA-2β) is of particular interest [42]. Inactivation of PTPRN2/phogrin, a secretory granule-localised protein [53], leads to defective insulin secretion in mice [54, 55]. Importantly, double knockout of PTPRN2/phogrin and the closely-related Ptprn (IA-2) gene leads to defective FSH and LH production and female infertility [54], implying an important role in the anterior pituitary. An interaction between C2CD4A or C2CD4B and PTPRN2 in the pituitary (and possibly the beta cell) may, therefore, contribute to the effects of altered expression on diabetes risk.

Limitations of the study

The present work was undertaken using animals on a mixed C57BL6N:C57BL6J background and future studies are required to confirm the findings here in pure-bred strains [56]. The impact of C2cd4b deletion on fertility, and on the role of C2cd4a and C2cd4b in the pituitary, remain to be explored, as does the contribution of changes in food intake or energy expenditure to differences in body weight. More work will also be necessary to determine whether c2cd4a-null zebrafish display beta cell deficiency.

Restrictions imposed by the coronavirus disease-2019 (COVID-19) pandemic prevented further explorations of these points during the present study.

Data availability

The datasets generated and/or analysed during the current study are available in the Biorxiv repository, (www.biorxiv.org/content/10.1101/2020.05.18.099200v1). RNA-Seq (GSE152576) and proteomics (PXD021597) data have been deposited to GEO (www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE152576) and ProteomeXchange (www.ebi.ac.uk/pride/archive/projects/PXD021597) repositories, respectively.

Abbreviations

C2CD:

C2 calcium dependent domain containing protein

E2:

Oestradiol

eQTL:

Expression quantitative trait locus

ER:

Endoplasmic reticulum

FSH:

Follicle-stimulating hormone

GFP:

Green fluorescent protein

GWAS:

Genome-wide association study

HFD:

High-fat and -sucrose diet

IA-2:

Insulinoma-associated protein 2

IMPC:

International Mouse Phenotyping Consortium

KREBH:

HEPES-buffered Krebs-Ringer medium

LH:

Luteinising hormone

PTPRN:

Receptor-type tyrosine-protein phosphatase-like N

RC:

Regular chow

Syt1:

Synaptotagmin-1

TIRF:

Total internal reflection of fluorescence

WT:

Wild-type

References

  1. Mahajan A, Taliun D, Thurner M et al (2018) Fine-mapping of an expanded set of type 2 diabetes loci to single-variant resolution using high-density imputation and islet-specific epigenome maps. Nat Genet:245506. https://doi.org/10.1101/245506

  2. Prokopenko I, McCarthy MI, Lindgren CM (2008) Type 2 diabetes: new genes, new understanding. Trends Genet 24(12):613–621. https://doi.org/10.1016/j.tig.2008.09.004

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  3. Carrat GR, Hu M, Nguyen-Tu M-S et al (2017) Decreased STARD10 Expression Is Associated with Defective Insulin Secretion in Humans and Mice. Am J Hum Genet 100(2):238–256. https://doi.org/10.1016/j.ajhg.2017.01.011

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  4. Rutter GA, Chimienti F (2015) SLC30A8 mutations in type 2 diabetes. Diabetologia 58(1):31–36. https://doi.org/10.1007/s00125-014-3405-7

    CAS  Article  PubMed  Google Scholar 

  5. Prokopenko I, Poon W, Mägi R et al (2014) A Central Role for GRB10 in Regulation of Islet Function in Man. PLoS Genet 10(4):1–13. https://doi.org/10.1371/journal.pgen.1004235

    CAS  Article  Google Scholar 

  6. Kumar N, Leonzino M, Hancock-Cerutti W et al (2018) VPS13A and VPS13C are lipid transport proteins differentially localized at ER contact sites. J Cell Biol 217(10):3625–3639. https://doi.org/10.1083/jcb.201807019

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  7. Mehta ZB, Fine N, Pullen TJ et al (2016) Changes in the expression of the type 2 diabetes-associated gene VPS13C in the β-cell are associated with glucose intolerance in humans and mice. Am J Physiol Endocrinol Metab 311(2):E488–E507. https://doi.org/10.1152/ajpendo.00074.2016

    Article  PubMed  PubMed Central  Google Scholar 

  8. Varshney A, Scott LJ, Welch RP et al (2017) Genetic regulatory signatures underlying islet gene expression and type 2 diabetes. Proc Natl Acad Sci 114(9):2301–2306. https://doi.org/10.1073/pnas.1621192114

    CAS  Article  PubMed  Google Scholar 

  9. Kycia I, Wolford BN, Huyghe JR et al (2018) A Common Type 2 Diabetes Risk Variant Potentiates Activity of an Evolutionarily Conserved Islet Stretch Enhancer and Increases C2CD4A and C2CD4B Expression. Am J Hum Genet 102(4):620–635. https://doi.org/10.1016/j.ajhg.2018.02.020

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  10. Warton K, Foster NC, Gold WA, Stanley KK (2004) A novel gene family induced by acute inflammation in endothelial cells. Gene 342(1):85–95. https://doi.org/10.1016/j.gene.2004.07.027

    CAS  Article  PubMed  Google Scholar 

  11. Omori H, Ogaki S, Sakano D et al (2016) Changes in expression of C2cd4c in pancreatic endocrine cells during pancreatic development. FEBS Lett 590:2584–2593. https://doi.org/10.1002/1873-3468.12271

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  12. Gilon P, Chae H-Y, Rutter GA, Ravier MA (2014) Calcium signaling in pancreatic β-cells in health and in Type 2 diabetes. Cell Calcium 56(5):340–361. https://doi.org/10.1016/j.ceca.2014.09.001

    CAS  Article  PubMed  Google Scholar 

  13. O’Hare EA, Yerges-Armstrong LM, Perry JA, Shuldiner AR, Zaghloul NA (2016) Assignment of functional relevance to genes at type 2 diabetes-associated loci through investigation of β-Cell mass deficits. Mol Endocrinol 30(4):429–445. https://doi.org/10.1210/me.2015-1243

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  14. Peiris H, Park S, Louis S et al (2018) Discovering human diabetes-risk gene function with genetics and physiological assays. Nat Commun 9(1):3855. https://doi.org/10.1038/s41467-018-06249-3

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  15. Kuo T, Kraakman MJ, Damle M, Gill R, Lazar MA, Accili D (2019) Identification of C2CD4A as a human diabetes susceptibility gene with a role in β cell insulin secretion. Proc Natl Acad Sci U S A 116(4):20033–20042. https://doi.org/10.1073/pnas.1904311116

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  16. Pullen TJ, Huising MO, Rutter GA (2017) Analysis of purified pancreatic islet beta and alpha cell transcriptomes reveals 11β-hydroxysteroid dehydrogenase (Hsd11b1) as a novel disallowed gene. Front Genet 8:41. https://doi.org/10.3389/fgene.2017.00041

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  17. Brouwers B, De Faudeur G, Osipovich AB et al (2014) Impaired islet function in commonly used transgenic mouse lines due to human growth hormone minigene expression. Cell Metab 20(6):979–990. https://doi.org/10.1016/j.cmet.2014.11.004

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  18. Owen BM, Bookout AL, Ding X et al (2013) FGF21 contributes to neuroendocrine control of female reproduction. Nat Med 19(9):1153–1156. https://doi.org/10.1038/nm.3250

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  19. Ravier MA, Rutter GA (2010) Isolation and culture of mouse pancreatic islets for ex vivo imaging studies with trappable or recombinant fluorescent probes. In: Ward A, Tosh D (eds) Mouse cell culture: methods and protocols. Humana Press, Totowa, pp 171–184

    Chapter  Google Scholar 

  20. Nguyen-Tu M-S, da Silva Xavier G, Leclerc I, Rutter GA (2018) Transcription factor-7-like 2 (TCF7L2) gene acts downstream of the Lkb1/Stk11 kinase to control mTOR signaling, β cell growth, and insulin secretion. J Biol Chem 293(36):14178–14189. https://doi.org/10.1074/jbc.RA118.003613

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  21. Hohmeier HE, Mulder H, Chen G, Henkel-Rieger R, Prentki M, Newgard CB (2000) Isolation of INS-1-derived cell lines with robust ATP-sensitive K+ channel-dependent and -independent glucose-stimulated insulin secretion. Diabetes 49(3):424–430. https://doi.org/10.2337/diabetes.49.3.424

    CAS  Article  PubMed  Google Scholar 

  22. Westerfield M (1995) The zebrafish book. A guide for the laboratory use of zebrafish (Danio rerio), 3rd edition. Univ Oregon Press, Eugene

    Google Scholar 

  23. Fisher S, Grice EA, Vinton RM et al (2006) Evaluating the biological relevance of putative enhancers using Tol2 transposon-mediated transgenesis in zebrafish. Nat Protoc 1(3):1297–1305. https://doi.org/10.1038/nprot.2006.230

    CAS  Article  PubMed  Google Scholar 

  24. Fisher S, Grice EA, Vinton RM, Bessling SL, McCallion AS (2006) Conservation of RET regulatory function from human to zebrafish without sequence similarity. Science 312(5771):276–279. https://doi.org/10.1126/science.1124070

    CAS  Article  PubMed  Google Scholar 

  25. Mavropoulos A, Devos N, Biemar F et al (2005) sox4b is a key player of pancreatic alpha cell differentiation in zebrafish. Dev Biol 285(1):211–223. https://doi.org/10.1016/j.ydbio.2005.06.024

    CAS  Article  PubMed  Google Scholar 

  26. Thisse C, Thisse B (2008) High-resolution in situ hybridization to whole-mount zebrafish embryos. Nat Protoc 3(1):59–69. https://doi.org/10.1038/nprot.2007.514

    CAS  Article  PubMed  Google Scholar 

  27. Flasse LC, Pirson JL, Stern DG et al (2013) Ascl1b and Neurod1, instead of Neurog3, control pancreatic endocrine cell fate in zebrafish. BMC Biol 11(1):78. https://doi.org/10.1186/1741-7007-11-78

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  28. Salem V, Silva LD, Suba K et al (2019) Leader β-cells coordinate Ca2+ dynamics across pancreatic islets in vivo. Nat Metab 1(6):615–629. https://doi.org/10.1038/s42255-019-0075-2

    CAS  Article  PubMed  Google Scholar 

  29. Hodson DJ, Mitchell RK, Bellomo EA et al (2013) Lipotoxicity disrupts incretin-regulated human β cell connectivity. J Clin Invest 123(10):4182–4194. https://doi.org/10.1172/JCI68459

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  30. Ravassard P, Hazhouz Y, Pechberty S et al (2011) A genetically engineered human pancreatic β cell line exhibiting glucose-inducible insulin secretion. J Clin Invest 121(9):3589–3597. https://doi.org/10.1172/JCI58447DS1

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  31. Miyazaki J-I, Araki K, Yamato E et al (1990) Establishment of a pancreatic β cell line that retains glucose-inducible insulin secretion: special reference to expression of glucose transporter isoforms. Endocrinology 127(1):126–132. https://doi.org/10.1210/endo-127-1-126

    CAS  Article  PubMed  Google Scholar 

  32. Millership SJ, Da Silva Xavier G, Choudhury AI et al (2018) Neuronatin regulates pancreatic β cell insulin content and secretion. J Clin Invest 128(8):3369–3381. https://doi.org/10.1172/JCI120115

    Article  PubMed  PubMed Central  Google Scholar 

  33. Benner C, van der Meulen T, Cacéres E, Tigyi K, Donaldson CJ, Huising MO (2014) The transcriptional landscape of mouse beta cells compared to human beta cells reveals notable species differences in long non-coding RNA and protein-coding gene expression. BMC Genomics 15(1):620. https://doi.org/10.1186/1471-2164-15-620

    Article  PubMed  PubMed Central  Google Scholar 

  34. Kone M, Pullen TJ, Sun G et al (2014) LKB1 and AMPK differentially regulate pancreatic β-cell identity. FASEB J 28(11):4972–4985. https://doi.org/10.1096/fj.14-257667

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  35. Marselli L, Thorne J, Dahiya S et al (2010) Gene expression profiles of Beta-cell enriched tissue obtained by laser capture microdissection from subjects with type 2 diabetes. PLoS One 5(7):e11499. https://doi.org/10.1371/journal.pone.0011499

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  36. Blodgett DM, Nowosielska A, Afik S et al (2015) Novel observations from next-generation RNA sequencing of highly purified human adult and fetal islet cell subsets. Diabetes 64(9):3172–3181. https://doi.org/10.2337/db15-0039

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  37. Cruciani-Guglielmacci C, Bellini L, Denom J et al (2017) Molecular phenotyping of multiple mouse strains under metabolic challenge uncovers a role for Elovl2 in glucose-induced insulin secretion. Mol Metab 6(4):340–351. https://doi.org/10.1016/j.molmet.2017.01.009

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  38. Solimena M, Schulte AM, Marselli L et al (2018) Systems biology of the IMIDIA biobank from organ donors and pancreatectomised patients defines a novel transcriptomic signature of islets from individuals with type 2 diabetes. Diabetologia 61(3):641–657. https://doi.org/10.1007/s00125-017-4500-3

    CAS  Article  PubMed  Google Scholar 

  39. Miguel-Escalada I, Bonàs-Guarch S, Cebola I et al (2019) Human pancreatic islet three-dimensional chromatin architecture provides insights into the genetics of type 2 diabetes. Nat Genet 51(7):1137–1148. https://doi.org/10.1038/s41588-019-0457-0

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  40. Idevall-hagren O, Lü A, Xie B, De Camilli P (2015) Triggered Ca 2 + influx is required for extended membrane tethering. EMBO J 34(17):2291–2305

    CAS  Article  Google Scholar 

  41. Shichiri M, Ishimaru S, Ota T, Nishikawa T, Isogai T, Hirata Y (2003) Salusins: newly identified bioactive peptides with hemodynamic and mitogenic activities. Nat Med 9(9):1166–1172. https://doi.org/10.1038/nm913

    CAS  Article  PubMed  Google Scholar 

  42. Suckale J, Solimena M (2010) The insulin secretory granule as a signaling hub. Trends Endocrinol Metab 21(10):599–609. https://doi.org/10.1016/j.tem.2010.06.003

    CAS  Article  PubMed  Google Scholar 

  43. Grarup N, Overvad M, Sparsø T et al (2011) The diabetogenic VPS13C/C2CD4A/C2CD4B rs7172432 variant impairs glucose-stimulated insulin response in 5,722 non-diabetic Danish individuals. Diabetologia 54(4):789–794. https://doi.org/10.1007/s00125-010-2031-2

    CAS  Article  PubMed  Google Scholar 

  44. Alonso-Magdalena P, Ropero AB, Carrera MP et al (2008) Pancreatic Insulin Content Regulation by the Estrogen Receptor ERα. PLoS One 3(4):e2069

    Article  Google Scholar 

  45. Mauvais-Jarvis F, Clegg DJ, Hevener AL (2013) The Role of Estrogens in Control of Energy Balance and Glucose Homeostasis. Endocr Rev 34(3):309–338. https://doi.org/10.1210/er.2012-1055

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  46. Saito T, Ciobotaru A, Bopassa JC, Toro L, Stefani E, Eghbali M (2009) Estrogen contributes to gender differences in mouse ventricular repolarization. Circ Res 105(4):343–352. https://doi.org/10.1161/CIRCRESAHA.108.190041

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  47. Mauvais-Jarvis F (2017) Epidemiology of gender differences in diabetes and obesity. In: Mauvais-Jarvis F (ed) Sex and gender factors affecting metabolic homeostasis, diabetes and obesity. Springer International Publishing, Cham, pp 3–8

    Chapter  Google Scholar 

  48. Strawbridge RJ, Dupuis J, Prokopenko I et al (2011) Genome-wide association identifies nine common variants associated with fasting proinsulin levels and provides new insights into the pathophysiology of type 2 diabetes. Diabetes 60(10):2624–2634. https://doi.org/10.2337/db11-0415

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  49. Mahajan A, Wessel J, Willems SM et al (2018) Refining the accuracy of validated target identification through coding variant fine-mapping in type 2 diabetes article. Nat Genet 50(4):559–571. https://doi.org/10.1038/s41588-018-0084-1

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  50. Ingvorsen C, Karp NA, Lelliott CJ (2017) The role of sex and body weight on the metabolic effects of high-fat diet in C57BL/6N mice. Nutr Diabetes 7(4):e261–e267. https://doi.org/10.1038/nutd.2017.6

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  51. Corbalán-García S, Gómez-Fernández JC (2010) The C2 domains of classical and novel PKCs as versatile decoders of membrane signals. BioFactors 36(1):1–7. https://doi.org/10.1002/biof.68

    CAS  Article  PubMed  Google Scholar 

  52. Nalefski EA, Falke JJ (1996) The C2 domain calcium-binding motif: Structural and functional diversity. Protein Sci 5(12):2375–2390. https://doi.org/10.1002/pro.5560051201

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  53. Pouli EA, Karajenc N, Wasmeier C et al (1998) A phogrin–aequorin chimaera to image free Ca2+ in the vicinity of secretory granules. Biochem J 330(3):1399–1404. https://doi.org/10.1042/bj3301399

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  54. Kubosaki A, Nakamura S, Clark A, Morris JF, Notkins AL (2006) Disruption of the transmembrane dense core vesicle proteins IA-2 and IA-2β causes female infertility. Endocrinology 147(2):811–815. https://doi.org/10.1210/en.2005-0638

    CAS  Article  PubMed  Google Scholar 

  55. Saeki K, Zhu M, Kubosaki A, Xie J, Lan MS, Notkins AL (2002) Targeted disruption of the protein tyrosine phosphatase-like molecule IA-2 results in alterations in glucose tolerance tests and insulin secretion. Diabetes 51(6):1842–1850. https://doi.org/10.2337/diabetes.51.6.1842

    CAS  Article  PubMed  Google Scholar 

  56. Fontaine DA, Davis DB (2016) Attention to Background Strain Is Essential for Metabolic Research: C57BL/6 and the International Knockout Mouse Consortium. Diabetes 65(1):25–33. https://doi.org/10.2337/db15-0982

    CAS  Article  PubMed  Google Scholar 

  57. Wang S, Li Y, Ma C (2016) Synaptotgmin-1 C2B domain interacts simultaneousy with SNAREs and membranes to promote membrane fusion. ELife 5:e14211. https://doi.org/10.7554/eLife.14211

    CAS  Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We thank I. Cebola (Division of Systems Medicine, Imperial College London, London, UK) for her comments and revision of the manuscript. We also thank S. Rothery and other members of the Imperial College Facility for Imaging by Light Microscopy (FILM; Imperial College London) for training and use of the wide-field and confocal microscope. We also thank H. M. Muhitu and X. Li (Section of Cell Biology and Functional Genomics, Imperial College London) for quantification of mouse islet beta cell mass and for plasmid cloning, respectively. This work was presented at the Diabetes UK Annual Conference Manchester (2017), Diabetes UK Annual Professional Conference (2018), and the EASD Annual Conference, Berlin (2018).

Authors’ relationships and activities

GAR has received grant funding and consultancy fees from Sun Pharmaceuticals and Les Laboratoires Servier. All other authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work.

Funding

GAR was supported by Wellcome Trust Senior Investigator (WT098424AIA) and Investigator (WT212625/Z/18/Z) awards, MRC Programme grants (MR/R022259/1, MR/J0003042/1, MR/L020149/1, MR/R022259/1) and Experimental Challenge Grant (DIVA, MR/L02036X/1), MRC (MR/N00275X/1), Diabetes UK grants (BDA/11/0004210, BDA/15/0005275, BDA 16/0005485) and Imperial Confidence in Concept (ICiC) grants. This project has received funding from the European Union’s Horizon 2020 research and innovation programme via the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115881 (RHAPSODY) to GAR. Work in the DJW laboratory was funded by the Medical Research Council (MC-A654-5QB40). SJM was supported by an Imperial College/Wellcome Trust ISSF Springboard Fellowship.

Author information

Authors and Affiliations

  1. Section of Cell Biology and Functional Genomics, Department of Metabolism, Digestion and Reproduction, Imperial College London, Hammersmith Hospital, London, UK

    S. Neda Mousavy Gharavy, Steven J. Millership, Pauline Chabosseau, Grazia Pizza, Aida Martinez-Sanchez, Eleni Georgiadou, Ming Hu, Nicholas H. F. Fine, Zenobia Mehta, Isabelle Leclerc & Guy A. Rutter

  2. Section of Investigative Medicine, Department of Metabolism, Digestion and Reproduction, Imperial College London, Hammersmith Hospital, London, UK

    Bryn M. Owen

  3. MRC London Institute of Medical Sciences, Imperial College London, Hammersmith Campus, London, UK

    Steven J. Millership, Alex Montoya, Holger Kramer & Dominic J. Withers

  4. Institute of Clinical Sciences, Faculty of Medicine, Imperial College London, London, UK

    Steven J. Millership & Dominic J. Withers

  5. DFG-Center for Regenerative Therapies, Technische Universität Dresden, Dresden, Germany

    Emirhan Tasoez & Nikolay Ninov

  6. Department of Molecular Physiology and Biophysics Vanderbilt University, Nashville, TN, USA

    David A. Jacobson & Matthew T. Dickerson

  7. Department of Medical Cell Biology, Uppsala University, Uppsala, Sweden

    Olof Idevall-Hagren

  8. Children’s Hospital of Philadelphia, CTRB, Philadelphia, PA, USA

    Paul J. Gadue & Fabian L. Cardenas-Diaz

  9. Regulation of Glycemia by Central Nervous System, BFA, UMR 8251, CNRS Université de Paris, Paris, France

    Céline Cruciani-Guglielmacci & Christophe Magnan

  10. Vital-IT Group, SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland

    Mark Ibberson

  11. Laboratory of Zebrafish Development and Disease Models, University of Liège (ULg), Liège, Belgium

    Marianne Voz

  12. Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore

    Guy A. Rutter

Authors
  1. S. Neda Mousavy Gharavy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bryn M. Owen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Steven J. Millership
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Pauline Chabosseau
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Grazia Pizza
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Aida Martinez-Sanchez
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Emirhan Tasoez
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Eleni Georgiadou
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ming Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Nicholas H. F. Fine
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. David A. Jacobson
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Matthew T. Dickerson
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Olof Idevall-Hagren
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Alex Montoya
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Holger Kramer
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Zenobia Mehta
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Dominic J. Withers
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Nikolay Ninov
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Paul J. Gadue
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Fabian L. Cardenas-Diaz
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. Céline Cruciani-Guglielmacci
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. Christophe Magnan
    View author publications

    You can also search for this author in PubMed Google Scholar

  23. Mark Ibberson
    View author publications

    You can also search for this author in PubMed Google Scholar

  24. Isabelle Leclerc
    View author publications

    You can also search for this author in PubMed Google Scholar

  25. Marianne Voz
    View author publications

    You can also search for this author in PubMed Google Scholar

  26. Guy A. Rutter
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

GAR, SNMG, NN, BMO and MV designed the research. SNMG, SJM, MV, NN and GAR wrote the manuscript. AM-S, AM, CC-G, CM, DAJ, ET, EG, MH, NHFF, MTD, HK, ZM, NN, SNMG, PC, GP, SJM, BMO, MV and MI performed all experiments and data analysis and revised the article. DJW, FLC-D, OI-H, IL, PJG and HK contributed reagents and revised the article. IL oversaw and helped design all animal procedures and liaised with the UK Home Office and local ethics committee over licensing for the work. All authors read and approved the manuscript and contributed according to the ICMJE criteria (www.icmje.org/). GAR supervised the work. GAR serves as the guarantor of this work

Corresponding author

Correspondence to Guy A. Rutter.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

ESM 1

(PDF 1711 kb)

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Mousavy Gharavy, S.N., Owen, B.M., Millership, S.J. et al. Sexually dimorphic roles for the type 2 diabetes-associated C2cd4b gene in murine glucose homeostasis. Diabetologia 64, 850–864 (2021). https://doi.org/10.1007/s00125-020-05350-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00125-020-05350-x

Keywords

  • C2CD4A/B
  • Follicle-stimulating hormone
  • Genome-wide association studies
  • Glucose homeostasis
  • Type 2 diabetes